Biotech and Pharmaceuticals
FDA approves leucovorin as first drug for rare genetic disorder, after touting it as autism treatment
FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009. Jason Reed | Reuters The Food and Drug Administration on Tuesday approved a decades-old prescription vitamin called leucovorin as the first treatment for a rare genetic disorder in certain adults and children. The move […]
Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration. The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]
Read More
Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’
Wegovy is produced by pharmaceutical company Novo Nordisk and has been approved for specifically for chronic weight management in adults and adolescents. (Photo by Steve Christo – Corbis/Corbis via Getty Images) Steve Christo – Corbis | Corbis News | Getty Images The chief executive of drugmaker Zealand Pharma sought to calm investors about the latest […]
Read More
Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.
Eli Lilly on Thursday launched a new program designed to help more employers cover obesity drugs in the U.S., targeting a major barrier to access for patients. Lilly and its chief rival, Novo Nordisk, have moved to slash the cash prices of their popular obesity injections for those who want to pay entirely out-of-pocket. But […]
Read More
Commit fully to the role you’re in now, and your career may thank you later: Novartis CEO Vas Narasimhan
Guided by immigrant roots, public‑health purpose and a belief in “staying in the ring,” Novartis CEO Vas Narasimhan reflects on the unlikely decisions that took him from the “steel town” of Pittsburgh, Pennsylvania to the helm of a global drugmaker. Source
Read More
Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly
Novo Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its production capacities to make the newly launched Wegovy pill, the Danish drugmaker said Monday. The news comes about two months after Novo launched its blockbuster weight loss drug Wegovy in pill form in the U.S. market, in […]
Read More
Here’s an update on our 4th Industrial Revolution stocks and the rest of the portfolio
On Friday, the CNBC Investing Club held its February Monthly Meeting, where Jim Cramer and Director of Portfolio Analysis ran through each stock in the portfolio. Jim put a special focus on the Club stocks within the artificial intelligence trade. He’s dubbed them the “Fourth Industrial Revolution stocks,” borrowing the term from Nvidia CEO Jensen […]
Read More
These 4 charts show the scale of Novo Nordisk’s woes
Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe’s most valuable company. But its troubles are stacking up and today the stock trades at just a quarter of what it did at its peak less than two years ago. Pricing pressure, fierce competition, and pipeline setbacks have […]
Read More
Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026. Tom Little | Reuters Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027, […]
Read More
Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion
A Gilead Sciences office is shown in Foster City, California, U.S. May 1, 2018. Stephen Lam | Reuters Gilead Sciences will pay as much as $7.8 billion to acquire partner Arcellx in its largest deal since 2020, the biopharma company said on Monday, as it looks to strengthen its lineup of cancer treatments. The company, […]
Read More